Dianthus Therapeutics, Inc.
DNTH
$85.74
-$0.41-0.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.34M | 2.04M | 3.08M | 4.85M | 6.52M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.34M | 2.04M | 3.08M | 4.85M | 6.52M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.34M | 2.04M | 3.08M | 4.85M | 6.52M |
| SG&A Expenses | 39.44M | 34.33M | 31.21M | 29.56M | 26.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 192.63M | 179.97M | 143.39M | 134.77M | 123.72M |
| Operating Income | -191.29M | -177.93M | -140.31M | -129.92M | -117.20M |
| Income Before Tax | -173.66M | -162.34M | -126.35M | -114.75M | -100.73M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -173.66 | -162.34 | -126.35 | -114.75 | -100.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -173.66M | -162.34M | -126.35M | -114.75M | -100.73M |
| EBIT | -191.29M | -177.93M | -140.31M | -129.92M | -117.20M |
| EBITDA | -191.17M | -177.82M | -140.20M | -129.81M | -117.10M |
| EPS Basic | -4.14 | -4.11 | -3.49 | -3.25 | -2.89 |
| Normalized Basic EPS | -2.68 | -2.68 | -2.32 | -2.18 | -1.94 |
| EPS Diluted | -4.14 | -4.11 | -3.49 | -3.25 | -2.89 |
| Normalized Diluted EPS | -2.68 | -2.68 | -2.32 | -2.18 | -1.94 |
| Average Basic Shares Outstanding | 166.62M | 154.38M | 144.44M | 140.88M | 139.29M |
| Average Diluted Shares Outstanding | 166.62M | 154.38M | 144.44M | 140.88M | 139.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |